WO2003082302A3 - Bioadhesive directed somatic cell therapy - Google Patents

Bioadhesive directed somatic cell therapy Download PDF

Info

Publication number
WO2003082302A3
WO2003082302A3 PCT/US2003/009719 US0309719W WO03082302A3 WO 2003082302 A3 WO2003082302 A3 WO 2003082302A3 US 0309719 W US0309719 W US 0309719W WO 03082302 A3 WO03082302 A3 WO 03082302A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioadhesive
cell therapy
somatic cell
directed somatic
directed
Prior art date
Application number
PCT/US2003/009719
Other languages
French (fr)
Other versions
WO2003082302A2 (en
WO2003082302A9 (en
Inventor
Sun Uk Song
Youngsuk Yi
Kwan Hee Lee
Moon Jong Noh
Original Assignee
Tissuegene Inc
Sun Uk Song
Youngsuk Yi
Kwan Hee Lee
Moon Jong Noh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissuegene Inc, Sun Uk Song, Youngsuk Yi, Kwan Hee Lee, Moon Jong Noh filed Critical Tissuegene Inc
Priority to JP2003579839A priority Critical patent/JP4451135B2/en
Priority to KR1020047015308A priority patent/KR100572217B1/en
Priority to AU2003218464A priority patent/AU2003218464B2/en
Priority to CA2480656A priority patent/CA2480656C/en
Priority to EP03714466A priority patent/EP1490075A4/en
Priority to CN038121778A priority patent/CN1655802B/en
Publication of WO2003082302A2 publication Critical patent/WO2003082302A2/en
Publication of WO2003082302A3 publication Critical patent/WO2003082302A3/en
Publication of WO2003082302A9 publication Critical patent/WO2003082302A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The subject invention is related to a cell-mediated gene therapy treatment using a cell composition that includes bioadhesive material. The bioadhesive material allows targeted and localized delivery of therapeutic somatic cells to the site of interest.
PCT/US2003/009719 2002-03-29 2003-03-28 Bioadhesive directed somatic cell therapy WO2003082302A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2003579839A JP4451135B2 (en) 2002-03-29 2003-03-28 Bioadhesion-directed somatic cell therapy
KR1020047015308A KR100572217B1 (en) 2002-03-29 2003-03-28 Bioadhesive directed somatic cell therapy
AU2003218464A AU2003218464B2 (en) 2002-03-29 2003-03-28 Bioadhesive directed somatic cell therapy
CA2480656A CA2480656C (en) 2002-03-29 2003-03-28 Bioadhesive directed somatic cell therapy
EP03714466A EP1490075A4 (en) 2002-03-29 2003-03-28 Bioadhesive directed somatic cell therapy
CN038121778A CN1655802B (en) 2002-03-29 2003-03-28 Bioadhesive directed somatic cell therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36911102P 2002-03-29 2002-03-29
US60/369,111 2002-03-29

Publications (3)

Publication Number Publication Date
WO2003082302A2 WO2003082302A2 (en) 2003-10-09
WO2003082302A3 true WO2003082302A3 (en) 2003-12-18
WO2003082302A9 WO2003082302A9 (en) 2005-01-20

Family

ID=28675567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009719 WO2003082302A2 (en) 2002-03-29 2003-03-28 Bioadhesive directed somatic cell therapy

Country Status (8)

Country Link
US (1) US7431922B2 (en)
EP (1) EP1490075A4 (en)
JP (1) JP4451135B2 (en)
KR (1) KR100572217B1 (en)
CN (1) CN1655802B (en)
AU (1) AU2003218464B2 (en)
CA (1) CA2480656C (en)
WO (1) WO2003082302A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005127B2 (en) * 2002-03-29 2006-02-28 Tissuegene, Inc. Mixed-cell gene therapy
DK1594973T3 (en) * 2003-02-10 2012-02-13 Max Delbrueck Centrum Transposon-based targeting system
BE1015610A3 (en) * 2003-07-17 2005-06-07 Corrutech Nv Improved glue and method for manufacturing same.
US7927599B2 (en) 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7897384B2 (en) 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
CA2599589A1 (en) * 2005-02-07 2006-08-17 Genenews,Inc. Mild osteoarthritis biomarkers and uses thereof
JP2009506982A (en) 2005-06-23 2009-02-19 ティシュージーン，インク Compounds with neuroprotective effect
US20140255364A1 (en) * 2011-10-28 2014-09-11 Tufts University 3d culture system for culturing cells in synovial fluid, cells cultured in synovial fluid and their use
KR20190003413A (en) * 2017-06-30 2019-01-09 코오롱생명과학 주식회사 A Pharmaceutical Composition For Preventing or Treating Osteoarthritis
JP7269231B2 (en) 2017-06-30 2023-05-08 コーロン ライフ サイエンス インコーポレイテッド Method for evaluating efficacy of cell therapy agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6151525A (en) * 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5858355A (en) 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
EP0690673A4 (en) 1993-12-14 1996-05-29 Univ Pittsburgh Systemic gene treatment of connective tissue diseases
US5965125A (en) * 1995-10-25 1999-10-12 Transkaryotic Therapies, Inc. Hybrid matrix implants and explants
US5842477A (en) 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
US5700774A (en) 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
US6291240B1 (en) * 1998-01-29 2001-09-18 Advanced Tissue Sciences, Inc. Cells or tissues with increased protein factors and methods of making and using same
US6315992B1 (en) 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
WO2003068800A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Isolated peptides which bind to hla molecules and uses thereof
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6151525A (en) * 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIGGESWARAPU ET AL.: "Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo", J. BONE AND JOINT SURG., vol. 83A, no. 3, March 2001 (2001-03-01), pages 364 - 376, XP009013151 *

Also Published As

Publication number Publication date
KR100572217B1 (en) 2006-04-24
AU2003218464A1 (en) 2003-10-13
EP1490075A4 (en) 2008-07-30
WO2003082302A2 (en) 2003-10-09
JP4451135B2 (en) 2010-04-14
EP1490075A2 (en) 2004-12-29
WO2003082302A9 (en) 2005-01-20
CA2480656A1 (en) 2003-10-09
US20040018179A1 (en) 2004-01-29
CN1655802A (en) 2005-08-17
US7431922B2 (en) 2008-10-07
KR20050002898A (en) 2005-01-10
CN1655802B (en) 2011-02-23
JP2005537222A (en) 2005-12-08
AU2003218464B2 (en) 2006-09-21
CA2480656C (en) 2013-09-24

Similar Documents

Publication Publication Date Title
IL267126B (en) Isolated human rpe cells and use thereof for the treatment of degenerative diseases of the retina
PL368243A1 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
AU2003261251A1 (en) Methods of delivering therapeutic agents
WO2003082302A3 (en) Bioadhesive directed somatic cell therapy
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
AU2003268206A1 (en) Microprotrusion arrays and methods for using same to deliver substances into tissue
WO2004064728A3 (en) Use of specific tetracycline compounds in therapy
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003216586A1 (en) Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
EP1663104A4 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
AU2002952597A0 (en) Topical parasiticide formulations and methods of treatment
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
AU2003294796A1 (en) Epothilone analogs for site specific delivery in the treatment of proliferative diseases
AU2003207426A1 (en) Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
AU2003295902A1 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
WO2006004774A3 (en) Laulimalide analogues as therapeutic agents
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
WO2005118789A3 (en) Therapeutic delivery of adenosine into a tissue
AU2003270540A1 (en) Treatment of cyclooxygenase-3 mediated diseases and disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2864/DELNP/2004

Country of ref document: IN

Ref document number: 2003714466

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020047015308

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003579839

Country of ref document: JP

Ref document number: 2480656

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003218464

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038121778

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003714466

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047015308

Country of ref document: KR

COP Corrected version of pamphlet

Free format text: PAGES 1-32, DESCRIPTION, REPLACED BY NEW PAGES 1-32; ; PAGES 33-37, CLAIMS, REPLACED BY NEW PAGES 33-37; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWG Wipo information: grant in national office

Ref document number: 1020047015308

Country of ref document: KR